
|Articles|April 15, 2019
Private equity and ophthalmology: Will I be left behind?
If you find yourself waffling back and forth on private equity, Ruth D. Williams, MD, has some guidance tips to make the decision easier.
Advertisement
Ruth D. Williams, MD, shares the take-home message from her presentation, "Private Equity and Ophthalmology: Will I Be Left Behind?" at the 23rd annual Glaucoma 360 meeting at the Palace Hotel in San Francisco on Feb. 2, 2019.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
What ‘I’m Fine’ Really Means: An Open Letter from a Thyroid Eye Disease (TED) Patient
2
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
3
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
4
AAO 2025: A study of retinal vasculitis events with intravitreal agents
5


















































.png)


